An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Aug 2012 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov record (extension study NCT01215513)
- 21 Aug 2012 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov record (extension study NCT01215513)
- 06 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record (Extension trial: NCT01215513).